High-Affinity GD2-specific CAR T cells induce fatal encephalitis in a preclinical neuroblastoma model

Cancer Immunology Research

Volumn 6, Issue 1, 2018, Pages 36-46

  Richman, Sarah A ^a   Nunez Cruz, Selene ^a   Moghimi, Babak ^a   Li, Lucy Z ^a   Gershenson, Zachary T ^a   Mourelatos, Zissimos ^a   Barrett, David M ^a   Grupp, Stephan A ^a   Milone, Michael C ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; GAMMA INTERFERON; GANGLIOSIDE GD2; IMMUNOGLOBULIN G2A; PLASMID DNA; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; CD3 ANTIGEN; CD3 ANTIGEN, ZETA CHAIN; GANGLIOSIDE; GANGLIOSIDE, GD2; LYMPHOCYTE ANTIGEN RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 9;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN REGION; CELL INFILTRATION; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; ENCEPHALITIS; EXPRESSION VECTOR; FLOW CYTOMETRY; GENE MUTATION; GENE SYNTHESIS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEUROBLASTOMA; NEUROBLASTOMA CELL; NEUROTOXICITY; NONHUMAN; PROMOTER REGION; PROTEIN STABILITY; PROTEIN TARGETING; SH-SY5Y CELL LINE; T LYMPHOCYTE; TUMOR XENOGRAFT; ADOPTIVE IMMUNOTHERAPY; ANIMAL; COMPLICATION; CYTOTOXICITY; DISEASE MODEL; DRUG SCREENING; GENE ORDER; GENE VECTOR; GENETICS; IMMUNOLOGY; METABOLISM; PROCEDURES; TUMOR CELL LINE;

ANIMALS; CD3 COMPLEX; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; ENCEPHALITIS; GANGLIOSIDES; GENE ORDER; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MICE; NEUROBLASTOMA; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, CHIMERIC ANTIGEN; SINGLE-CHAIN ANTIBODIES; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 9; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85040448741     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-17-0211     Document Type: Article

References (33)

1. Schulz G, Cheresh DA, Varki NM, Yu A, Staffileno LK, Reisfeld RA. Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res 1984;44:5914-20.
2. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009;15: 5323-37.
3. Lammie G, Cheung N, Gerald W, Rosenblum M, Cordoncardo C. Ganglioside gd(2) expression in the human nervous-system and in neuroblastomas - an immunohistochemical study. Int J Oncol 1993;3:909-15.
4. Furukawa K, Aixinjueluo W, Kasama T, Ohkawa Y, Yoshihara M, Ohmi Y, et al. Disruption of GM2/GD2 synthase gene resulted in overt expression of 9-O-acetyl GD3 irrespective of Tis21. J Neurochem 2008; 105:1057-66.
5. Svennerholm L, Bostrom K, Fredman P, Jungbjer B, Lekman A, Mansson JE, et al. Gangliosides and allied glycosphingolipids in human peripheral nerve and spinal cord. Biochim Biophys Acta 1994;1214: 115-23.
6. Dong L, Liu Y, Colberg-Poley AM, Kaucic K, Ladisch S. Induction of GM1a/GD1b synthase triggers complex ganglioside expression and alters neuroblastoma cell behavior; a new tumor cell model of ganglioside function. Glycoconj J 2011;28:137-47.
7. Cazet A, Bobowski M, Rombouts Y, Lefebvre J, Steenackers A, Popa I, et al. The ganglioside G(D2) induces the constitutive activation of c-Met in MDA-MB-231 breast cancer cells expressing the G(D3) synthase. Glycobiology 2012;22:806-16.
8. Furukawa K, Hamamura K, Aixinjueluo W, Furukawa K. Biosignals modulated by tumor-associated carbohydrate antigens: novel targets for cancer therapy. Ann N Y Acad Sci 2006;1086:185-98.
9. Hettmer S, McCarter R., Ladisch S, Kaucic K. Alterations in neuroblastoma ganglioside synthesis by induction of GD1b synthase by retinoic acid. Br J Cancer 2004;91:389-97.
10. Dobrenkov K, Ostrovnaya I, Gu J, Cheung IY, Cheung NK. Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults. Pediatr Blood Cancer 2016;63:1780-5.
11. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, et al. Virus-specific T cells engineeredto coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008;14:1264-70.
12. Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 2011;118:6050-6.
13. Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, Suhoski MM, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc. Nat. Acad. Sci. U S A 2009;106:3360-5.
14. Hudecek M, Lupo-Stanghellini MT, Kosasih PL, Sommermeyer D, Jensen MC, Rader C, et al. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res 2013;19:3153-64.
15. Hudecek M, Sommermeyer D, Kosasih PL, Silva-Benedict A, Liu L, Rader C, et al. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol Res 2015;3:125-35.
16. Liu X, Jiang S, Fang C, Yang S, Olalere D, Pequignot EC, et al. Affinity-Tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice. Cancer Res 2015;75:3596-607.
17. Rossig C, Bollard CM, Nuchtern JG, Merchant DA, Brenner MK. Targeting of G(D2)-positive tumor cellsbyhumanTlymphocytes engineeredtoexpress chimeric T-cell receptor genes. Int J Cancer 2001;94:228-36.
18. Ahmed M, Hu J, Cheung NK. Structure based refinement of a humanized monoclonal antibody that targets tumor antigen disialoganglioside GD2. Front Immunol 2014;5:372.
19. Ellebrecht CT, Bhoj VG, Nace A, Choi EJ, Mao X, Cho MJ, et al. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science 2016;353:179-84.
20. Wang E, Wang LC, Tsai CY, Bhoj V, Gershenson Z, Moon E, et al. Generation of potent T-cell immunotherapy for cancer using DAP12-Based, multichain, chimeric immunoreceptors. Cancer Immunol Res 2015;3:815-26.
21. Reid GS, Shan X, Coughlin CM, Lassoued W, Pawel BR, Wexler LH, et al. Interferon-gamma-dependent infiltration of humanTcells into neuroblastoma tumors in vivo. Clin Cancer Res 2009;15:6602-8.
22. Kochenderfer JN, Feldman SA, Zhao Y, Xu H, Black MA, Morgan RA, et al. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother 2009;32:689-702.
23. Singh N, Liu X, Hulitt J, Jiang S, June CH, Grupp SA, et al. Nature of tumor control by permanently and transiently modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma. Cancer Immunol Res 2014;2:1059-70.
24. Hudson PJ, Kortt AA. High avidity scFv multimers; diabodies and triabodies. J Immunol Methods 1999;231:177-89.
25. Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med 2015;21: 581-90.
26. Cheung NK, Guo H, Hu J, Tassev DV, Cheung IY. Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cellmediated cytotoxicity while retaining targeting in vivo. Oncoimmunology 2012;1:477-486.
27. Horwacik I, Golik P, Grudnik P, Kolinski M, Zdzalik M, Rokita H, et al. Structural basis of GD2 ganglioside and mimetic peptide recognition by 14G2a antibody. Mol Cell Proteomics 2015;14: 2577-90.
28. Chmielewski M, Hombach A, Heuser C, Adams GP, Abken H. T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity. J Immunol 2004;173:7647-53.
29. Hartrampf S, Dudakov JA, Johnson LK, Smith OM, Tsai J, Singer NV, et al. The central nervous system is a target of acute graft versus host disease in mice. Blood 2013;121:1906-10.
30. Kochenderfer JN, Yu Z, Frasheri D, Restifo NP, Rosenberg SA. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood 2010;116:3875-86.
31. Roybal KT, Rupp LJ, Morsut L, Walker WJ, McNally KA, Park JS, et al. Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. Cell 2016;164:770-9.
32. Fedorov VD, Themeli M, Sadelain M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med 2013;5:215ra172.
33. Turtle CJ, Hanafi LA, Berger C, Hudecek M, Pender B, Robinson E, et al. Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med 2016;8:355ra116.